Allergan PLC.’s (NYSE:AGN) “Outperform” Rating Reaffirmed at UBS AG
Allergan PLC. (NYSE:AGN)‘s stock had its “outperform” rating restated by investment analysts at UBS AG in a report issued on Wednesday, www.flashratings.com reports. They presently have a $275.00 price target on the stock. UBS AG’s target price would suggest a potential upside of 15.56% from the company’s current price.
AGN has been the topic of several other reports. Mizuho reiterated a “buy” rating and set a $267.00 target price on shares of Allergan PLC. in a report on Wednesday, August 2nd. Royal Bank Of Canada set a $285.00 target price on Allergan PLC. and gave the company a “buy” rating in a report on Thursday, August 3rd. Wells Fargo & Company raised their target price on Allergan PLC. to $278.00 and gave the company an “outperform” rating in a report on Thursday, August 3rd. Deutsche Bank AG reiterated a “buy” rating and set a $273.00 target price (up from $265.00) on shares of Allergan PLC. in a report on Monday, July 17th. Finally, Vetr upgraded Allergan PLC. from a “sell” rating to a “hold” rating and set a $242.88 target price on the stock in a report on Monday, June 26th. Eight equities research analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus price target of $274.49.
Allergan PLC. (NYSE AGN) traded down 0.74% during trading on Wednesday, reaching $237.97. The company’s stock had a trading volume of 2,019,325 shares. Allergan PLC. has a 1-year low of $184.50 and a 1-year high of $256.80. The company has a market capitalization of $79.93 billion, a P/E ratio of 7.41 and a beta of 1.16. The company’s 50-day moving average is $246.48 and its 200-day moving average is $237.35.
Allergan PLC. (NYSE:AGN) last released its quarterly earnings data on Thursday, August 3rd. The company reported $4.02 EPS for the quarter, topping analysts’ consensus estimates of $3.95 by $0.07. The company had revenue of $4.01 billion for the quarter, compared to the consensus estimate of $3.95 billion. Allergan PLC. had a return on equity of 7.25% and a net margin of 79.17%. The company’s quarterly revenue was up 8.8% compared to the same quarter last year. During the same period last year, the business posted $3.35 EPS. Equities analysts anticipate that Allergan PLC. will post $16.21 EPS for the current year.
In other news, Director Nesli Basgoz sold 1,889 shares of Allergan PLC. stock in a transaction that occurred on Thursday, May 18th. The stock was sold at an average price of $220.45, for a total value of $416,430.05. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 0.36% of the stock is currently owned by company insiders.
Several hedge funds and other institutional investors have recently modified their holdings of AGN. Trust Co. of Vermont raised its position in shares of Allergan PLC. by 62.8% in the first quarter. Trust Co. of Vermont now owns 2,875 shares of the company’s stock valued at $687,000 after buying an additional 1,109 shares during the last quarter. Israel Discount Bank of New York purchased a new position in shares of Allergan PLC. during the first quarter valued at approximately $988,000. BKD Wealth Advisors LLC purchased a new position in shares of Allergan PLC. during the first quarter valued at approximately $219,000. Rehmann Capital Advisory Group raised its position in shares of Allergan PLC. by 15.4% in the first quarter. Rehmann Capital Advisory Group now owns 1,780 shares of the company’s stock valued at $425,000 after buying an additional 237 shares during the last quarter. Finally, Excalibur Management Corp purchased a new position in shares of Allergan PLC. during the first quarter valued at approximately $218,000. Institutional investors own 84.77% of the company’s stock.
About Allergan PLC.
Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.
Receive News & Ratings for Allergan PLC. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC. and related companies with Analyst Ratings Network's FREE daily email newsletter.